More than 20,000 people are taking Eli Lilly's weight loss pill Foundayo, CEO says

Eli Lilly's weight loss pill launch has been closely watched after the successful start of Novo Nordisk's Wegovy pill.
24/7 Wall St. on MSN

Fast Money panel says Novo Nordisk now more compelling than Eli Lilly after falling 70%

Quick Read CNBC’s Fast Money panel argues Novo Nordisk (NVO) now offers better value than Eli Lilly (LLY) after NVO’s 68% ...

Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early February, and the gap ...

The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust

And can Novo Nordisk catch up to its rival in the weight loss market?

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth

Surging consumer demand for blockbuster weight-loss drugs helped offset their declining prices.
AOL

Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?

Eli Lilly's weight loss medicine, Zepbound, and Novo Nordisk's Wegovy have gone head-to-head in a clinical trial. The former emerged victorious, leading to a mean weight loss of 20.2% compared ...

Eli Lilly Expected to Post Higher 1Q Profit, Revenue on Continued Weight-Loss Drug Demand -- Earnings Preview

Eli Lilly is set to report first-quarter results before the market opens Thursday. Here is what you need to know. PROFIT: The pharmaceutical company is projected to post a profit of $6.61 billion, ...

Novo Nordisk Expands GLP-1 Reach With Oral Ozempic And Pediatric Push

Novo Nordisk (NYSE:NVO) is advancing the launch of an oral version of Ozempic, expanding its GLP-1 diabetes franchise beyond injectable formats. The company is also seeking regulatory approvals to ...